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challenges in Developing 
evidence-Based Drug Dosing 
Guidelines for adults and 
children receiving renal 
replacement therapy
BA Mueller1 and WE Smoyer2
The challenges of appropriate drug dosing in patients with renal 
failure requiring renal replacement therapy (rrT) have been 
exacerbated by recent trends in both rrT technology and practices. 
nearly all these changes have resulted in augmented drug clearance, 
making most existing rrT drug dosing recommendations obsolete. 
many barriers exist to conducting research to update our knowledge 
of appropriate drug dosing in the context of contemporary rrT. 
recommendations on how this research could be conducted, 
including the use of in vitro techniques, are offered here.
At some point, virtually all clinicians are 
asked to prescribe drugs to patients with 
renal failure. Pharmacotherapy is the 
cornerstone of much of the treatment of 
these patients. Indeed, the average adult 
hemodialysis patient takes 10–12 medica-
tions daily.1 Drug therapy in patients with 
renal failure is fundamentally different 
from that in patients with normal renal 
function for considerations related to 
pharmacokinetics and renal replacement 
therapy (RRT). This is true not only for 
drugs that are removed primarily by the 
kidneys but also for those that are not.2 
As a result, patients with renal disease are 
at increased risk for medication-related 
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the current dilemma
The RRT technologies and nephrology 
practices on which the FDA guidance 
was based have evolved significantly over 
the last several years, as the vancomycin 
example above illustrates. This evolution 
has created huge knowledge deficits in 
how to dose drugs appropriately. When we 
recently co-authored a renal drug dosing 
text we were concerned to find that CRRT 
drug dosing studies have been conducted 
for <20% of currently used drugs.6 Fur-
thermore, pharmacokinetic studies in 
newer hybrid RRTs, including slow low-
efficiency dialysis and extended daily 
dialysis, have been conducted for <1% 
of marketed drugs. Importantly, dosing 
recommendations for one form of RRT 
usually cannot be applied to other forms 
of RRT. The cumulative consequence of 
all of these RRT advances is that clinicians 
now have dangerously little information 
to guide the safe and effective dosing of 
the vast majority of drugs used in patients 
requiring RRT.
In this context, the vancomycin exam-
ple above exemplifies a larger problem. 
Clinicians are very familiar with and 
knowledgeable about vancomycin, and 
it has been used for more than 50 years. 
Were it not for the fact that we can easily 
measure vancomycin serum concentra-
tions, we would probably not even appre-
ciate how significantly the changes in RRT 
have influenced vancomycin clearance. 
More concerning is the fact that clini-
cians are faced with dosing hundreds of 
other drugs that have been studied far less 
than vancomycin and for which serum 
concentrations cannot be measured in 
a clinical laboratory. The effects that the 
recent changes in RRT have had on the 
pharmacokinetics of these agents are also 
obviously unknown. Our greatest concern 
is that there currently is no clear plan to 
ensure the development of this knowl-
edge, which is critical for the safe and 
effective use of drugs (both current and 
future) during RRT. With this in mind, we 
make the following suggestions to bridge 
this knowledge gap for pharmacotherapy 
in patients receiving RRT.
recommendations
The 1998 FDA guidance and subsequent 
preliminary concept paper7 provide 
patients, with the dose often given during 
the last 60–90 minutes of hemodialysis 
because only a small amount was removed 
by the dialysis procedure. In marked con-
trast, contemporary hemodialyzers are 
highly permeable and quite capable of 
clearing significant amounts of vanco-
mycin. Today, a 1,000-mg dose of vanco-
mycin once weekly during hemodialysis 
will almost certainly result in significant 
underdosing in an adult with renal fail-
ure. Similarly, contemporary continuous 
cycling peritoneal dialysis, using more 
rapid exchanges and “cyclers” to make 
these dialysate exchanges, also probably 
requires different vancomycin dosing 
regimens than those used with continuous 
ambulatory peritoneal dialysis. Even origi-
nal articles describing vancomycin dosing 
in continuous renal replacement therapy 
(CRRT) used less efficient hemodiafilters 
and lower dialysate flow rates than those 
used today. Consequently, although few 
data are available, the vancomycin doses 
needed for higher-volume CRRT are 
clearly greater than in the past.
Whereas advances in RRT technology 
and clinical practice have necessitated 
changes in how vancomycin is dosed, the 
most recent FDA-approved vancomycin 
package insert that we could identify 
makes no mention of dosing recommen-
dations for peritoneal dialysis or CRRT.5 
Indeed, drug clearance data for hemodi-
alysis or CRRT are not mentioned, and 
only a recommendation of 1,000 mg every 
7–10 days for anuric patients is made.5 
Clearly, strict adherence to the current 
vancomycin package insert while treating 
patients with contemporary RRT would 
systematically underdose patients and 
probably jeopardize, rather than enhance, 
patient safety.
problems.3 Appropriate drug dosing is 
thus a major challenge in these patients, 
and clinicians look to the research litera-
ture to provide guidance. Unfortunately, 
there is a paucity of published data that 
can be applied to these dosing situations, 
and the current, 11-year-old US Food and 
Drug Administration (FDA) Guidance 
for Pharmacokinetics in Patients with 
Impaired Renal Function4 has gradually 
been made obsolete as RRT technology 
and clinical practices have evolved.
The types and use of RRT have changed 
dramatically over the last several years, 
mainly as a result of technological 
advances. The RRT of the 1980s and 
1990s bears little resemblance to today’s 
RRT (Table 1). In nearly all cases, the 
changes in RRT have resulted in greater 
drug clearances. The clinical dilemma 
caused by these advances is that the phar-
macokinetic studies that formed the basis 
for many of the drug dosing recommen-
dations used today were derived in the 
1980s and 1990s using RRT techniques 
and technologies that are no longer used 
in current practice.
the example of vancomycin
Vancomycin is commonly used in patients 
requiring RRT, usually because of the 
high rate of gram-positive infections in 
these patients. Because vancomycin is 
cleared primarily by the kidneys, dosing 
of this drug must be adjusted in patients 
receiving RRT. In this setting, serum 
concentration monitoring can be used 
to guide these dosing decisions. Early 
pharmacokinetic studies conducted in 
the 1980s suggested that vancomycin was 
not significantly cleared by hemodialysis. 
Consequently, 1,000 mg of vancomycin 
was dosed once weekly in hemodialysis 
table 1 renal replacement therapy trends resulting in augmented drug clearance
1990s 2009
Low-permeability dialyzers High-permeability dialyzers
Dialysis dose not quantified Kt/Vurea target ≥1.2
Dialyzer membranes less biocompatible Dialyzer membranes more biocompatible
Smaller surface area dialyzers Larger surface area dialyzers
Continuous ambulatory peritoneal dialysis Continuous cycling peritoneal dialysis 
Lower effluent volume continuous renal 
replacement therapies 
Higher effluent volume continuous renal 
replacement therapies 
Kt/Vurea  dose of dialysis using urea clearance, dialysis duration, and patient size.
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filters, preferably the two most common in 
clinical practice at the time. Such studies 
should specify the dialyzer surface area 
(absolute and relative to patient surface 
area) and the ultrafiltration coefficient.
CRRT pharmacokinetic studies should 
also be performed in pediatric patients 
using pediatric hemofilters. Although the 
above suggestions will greatly improve 
rational drug dosing during CRRT in 
adults, children with AKI are typically 
forced to use adult CRRT equipment and 
adult-sized hemofilters because pediatric-
specific equipment is often unavailable. 
The use of such oversized filters often 
results in significant distortions in drug 
pharmacokinetics, particularly in smaller 
children and infants, and can thus greatly 
affect both drug efficacy and safety.
Barriers and potential solutions
The current FDA guidance recommends 
that pharmacokinetic studies be con-
ducted solely in hemodialysis for selected 
drugs likely to be cleared by hemodialysis. 
In light of the markedly increased usage of 
CRRT, the addition of a request for CRRT 
drug clearance data and dosing recom-
mendations to the 2008 FDA prelimi-
nary concept paper7 would significantly 
improve the safety and efficacy of drugs 
used in critically ill adults and children 
with AKI. Ideally, this information would 
be generated from clinical trials conducted 
in critically ill adult and pediatric patients. 
when total effluent rates are used to gener-
ate CRRT drug clearance estimates. Given 
that CVVHD is the most widely used type 
of CRRT, pharmacokinetic data from 
CVVHD would have the broadest appli-
cability to assist clinicians in determin-
ing appropriate drug dosing during any 
type of CRRT with conventional effluent 
rates.
The dose of delivered therapy for CRRT 
pharmacokinetic studies should be 35 ml/h/
kg (or 2,000 ml/h/1.73 m2). This sugges-
tion is evidence based, because this dose 
of CRRT has been demonstrated to pro-
vide superior patient outcomes in adults.9 
Although other important trials have 
shown that lower effluent rates are asso-
ciated with similar patient outcomes,10 
RRT doses in this range are currently used 
widely throughout the world in both adult 
and pediatric patients. Although some 
centers use higher or lower rates than this, 
this rate represents a compromise that will 
have applicability to most CRRT practices 
worldwide.
CRRT pharmacokinetic studies should be 
performed with the most commonly used 
hemofilters in contemporary practice. There 
is a wide variety of CRRT hemofilters, and 
each has different effects on transmem-
brane drug clearance (from data in our 
laboratory and others). Thus, to ensure the 
broadest applicability in practice, CRRT 
pharmacokinetic studies should be per-
formed using two different CRRT hemo-
appropriate direction for identifying 
which drugs should have pharmaco kinetic 
studies conducted in patients with renal 
disease. Since then, however, both the 
treatments of acute kidney injury (AKI) 
and chronic kidney disease and dialysis 
technologies have changed considerably. 
Based on these advances, we suggest the 
following approaches.
Hemodialysis. For drugs likely to be 
removed by hemodialysis, all hemodi-
alysis pharmacokinetic studies should be 
conducted using a standardized “dose” of 
hemodialysis using a kT/Vurea of ≥1.2. In 
the current guidance, the suggested hemo-
dialysis pharmacokinetic studies do not 
specify dialysis dose. However, the most 
recent National Kidney Foundation–Kid-
ney Disease Outcomes Quality Initiative 
guidelines8 identify the dose of hemodial-
ysis that is associated with optimal patient 
outcomes as a kT/Vurea of ≥1.2.
All hemodialysis pharmacokinetic stud-
ies should use hemodialyzers of a stand-
ardized surface area and ultrafiltration 
coefficient. Hemodialysis pharmaco kinetic 
studies should be conducted with high-
permeability hemodialysis membranes, as 
are used in the majority of contemporary 
practice.
All hemodialysis pharmacokinetic studies 
should be performed in pediatric patients 
using pediatric hemodialyzers. Such stud-
ies should specify the dialyzer surface area 
(absolute and relative to patient surface 
area), as well as the hemodialysis dose 
(kT/Vurea) used.
Continuous renal replacement ther-
apy. For all drugs likely to be used in the 
critical care environment and likely to 
have pharmacokinetics affected by CRRT, 
CRRT pharmacokinetic studies should 
be performed.
Although many types of CRRT exist, for 
standardization purposes, all CRRT phar-
macokinetic studies should be performed 
using continuous venovenous hemodi-
alysis (CVVHD). Drug clearance differ-
ences at conventional effluent (dialysate 
+ formed ultrafiltrate) rates are usually 
not substantially different among any of 
the CRRT modalities for the same total 
effluent rate. Studies showing differing 
clearance rates between CVVHD and 
other forms of CRRT are generally found 
not to be clinically significantly different 
table 2  Barriers to conducting renal replacement therapy research
General lack of drug assay availability for overwhelming majority of drugs
No governmental requirement/guidance for pharmaceutical or medical device companies to conduct 
CRRT pharmacokinetic studies
Funding CRRT pharmacokinetic studies could delay time to market for investigational drugs and 
devices
Funding CRRT pharmacokinetic studies would increase cost of drug and device development
A requirement of CRRT pharmacokinetic studies for drugs on patent could divert phase IV research 
funds from other studies
A requirement of CRRT pharmacokinetic studies for generic drugs may fall on manufacturers with 
limited research and development funds
No readily available research funding source, because this research is not hypothesis driven
Small numbers of CRRT patients at any  one site to study
Necessity of multicenter trials
IRB approval across multiple centers is difficult
Increased expense
Subject variability can be large, especially for critically ill subjects
CRRT, continuous renal replacement therapy; IRB, institutional review board.
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the study population could relatively eas-
ily lead to better and safer initial dosing 
estimates that should then be confirmed 
in subsequent clinical trials.
conclusion
Significant barriers exist to the devel-
opment of clinical and in vitro studies 
to enhance evidence-based drug dos-
ing during RRT. However, significant 
potential opportunities for enhancing 
their development also exist, including 
governmental guidance and support to 
conduct these studies. Implementation of 
the approaches proposed above by incor-
porating them into the planned update of 
the FDA Guidance for Pharmaco kinetics 
in Patients with Impaired Renal Func-
tion4 would provide vital information to 
clinicians facing the conundrum of deter-
mining appropriate drug dosing in adults 
and children receiving RRT. In addition, 
it would almost certainly result in more 
efficacious and safer pharmacotherapeutic 
outcomes, as well as more efficient use of 
health-care resources.
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Development of CRRT drug dosing rec-
ommendations for critically ill children 
and adults would be challenging, but tens 
of thousands of patients are already being 
treated with these modalities annually, 
largely without any available recommen-
dations to direct their pharmacotherapy. 
In the absence of pharmacokinetic stud-
ies conducted in critically ill patients with 
AKI, even dosing recommendations based 
on CRRT clearance estimates derived from 
in vitro drug clearance studies would be 
helpful. Those CRRT clearance estimates, 
combined with knowledge of the complex 
pharmacokinetic changes that occur in 
critically ill patients with AKI, would be 
far superior to what is currently available 
to clinicians.
Although many thousands of adults 
and children would benefit from clinical 
research in this area, many barriers exist 
to this type of research (Table 2). Despite 
these barriers, viable alternatives to pro-
spective RRT clinical pharmacokinetic 
trials already exist. Several solute clear-
ance studies using in vitro hemodialysis 
and CRRT circuits have shown potential 
usefulness in developing clinical dosing 
guidelines.11–13 There may be significant 
advantages of this approach, including 
elimination of patient risk, reduced time 
and cost, the ability to easily replicate 
many types of RRTs, and reduced study 
administration requirements (e.g., per-
taining to institutional review boards, 
informed consent, and subject recruit-
ment). Application of in vitro findings to 
known pharmacokinetic parameters in 
